Previous 10 | Next 10 |
Genocea Biosciences (NASDAQ: GNCA ) has priced its public offering of 10.5M common shares at $3.50/share, for gross proceeds of $36.75M. More news on: Genocea Biosciences, Inc., Healthcare stocks news, Read more ...
CAMBRIDGE, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the pricing of its previously announced underwritten public offering of 10,500,000 shares of its comm...
In my previous Genocea ( GNCA ) article , I initially expressed my belief therapeutic herpes simplex vaccine GEN-003 produced mixed results and wouldn't enter Phase 3 clinical studies. Due to objections from readers, I edited my article eliminating my opinion because to defend it would requir...
Gainers: Melinta Therapeutics (NASDAQ: MLNT ) +180% . Arcturus Therapeutics (NASDAQ: ARCT ) +37% . Hebron Technology (NASDAQ: HEBT ) +26% . MYOS RENS Technology (NASDAQ: MYOS ) +22% . Armata Pharmaceuticals (NYSEMKT: ARMP ) +19% . AquaBounty Technologies (NASDAQ: AQB ) +19% . D...
Sesen Bio (NASDAQ: SESN ) -32% on pricing equity offering. More news on: Sesen Bio, Inc., Tonix Pharmaceuticals Holding Corp., Calithera Biosciences, Inc., Stocks on the move, Read more ...
Genocea Biosciences (NASDAQ: GNCA ) down 5.1% AH, as the company commenced public offering of 10M. More news on: Genocea Biosciences, Inc., Healthcare stocks news, Read more ...
CAMBRIDGE, Mass., June 18, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has commenced an underwritten public offering of 10,000,000 shares of its common stock. All t...
INSYS Therapeutics (NASDAQ: INSY ) -63% on filing Chapter 11 for bankruptcy. More news on: INSYS Therapeutics, Inc., Spark Therapeutics, Inc., Genocea Biosciences, Inc., Stocks on the move, Read more ...
Genocea Biosciences (NASDAQ: GNCA ) is 8.4% lower postmarket after filing to offer up to $50M worth of stock. More news on: Genocea Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Genocea Biosciences ( GNCA ) presented some outstanding immunogenicity data at the American Society for Clinical Oncology ((ASCO)) 2019 medical meeting. It highlighted initial data from its phase 1/2a study using its neoantigen vaccine GEN-009. While this was just immunogenicity data, it was...
News, Short Squeeze, Breakout and More Instantly...
Genocea Biosciences Inc. Company Name:
GNCA Stock Symbol:
NASDAQ Market:
Genocea Biosciences Inc. Website: